José Garnacho-Montero1, George Dimopoulos2, Garyphallia Poulakou3, Murat Akova4, José Miguel Cisneros5, Jan De Waele6, Nicola Petrosillo7, Harald Seifert8,9, Jean François Timsit10,11, Jordi Vila12, Jean-Ralph Zahar13, Matteo Bassetti14. 1. Unidad Clínica de Cuidados Intensivos, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Seville, Spain. jgarnachom@gmail.com. 2. Department of Critical Care, University Hospital ATTIKON, Medical School, University of Athens, Athens, Greece. 3. 4th Department of Internal Medicine, Athens University School of Medicine, Attikon University General Hospital, Athens, Greece. 4. Department of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey. 5. Unidad Clínicia de Enfermedades Infecciosas, Microbiología y Preventiva, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Seville, Spain. 6. Department of Critical Care Medicine, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium. 7. 2nd Infectious Disease Division, National Institute for Infectious Diseases 'L. Spallanzani', Rome, Italy. 8. Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany. 9. German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany. 10. Medical and Infectious Diseases ICU, Bichat Hospital, 75018, Paris, France. 11. University Paris-Diderot - Inserm U1137 - IAME, 75018, Paris, France. 12. Department of Clinical Microbiology, CDB, Hospital Clínic, School of Medicine, University of Barcelona, Centre for International Health Research, (CRESIB-Hospital Clínic), Barcelona, Spain. 13. Unité de Prévention et de Lutte Contre les Infections Nosocomiales, Université d'Angers, Centre Hospitalo-universitaire d'Angers, Angers, France. 14. Infectious Diseases Clinic, Santa Maria Misericordia University Hospital, Udine, Italy.
Abstract
INTRODUCTION: Acinetobacter baumannii constitutes a dreadful problem in many ICUs worldwide. The very limited therapeutic options available for these organisms are a matter of great concern. No specific guidelines exist addressing the prevention and management of A. baumannii infections in the critical care setting. METHODS: Clinical microbiologists, infectious disease specialists and intensive care physicians were invited by the Chair of the Infection Section of the ESICM to participate in a multidisciplinary expert panel. After the selection of clinically relevant questions, this document provides recommendations about the use of microbiological techniques for identification of A. baumannii in clinical laboratories, antibiotic therapy for severe infections and recommendations to control this pathogen in outbreaks and endemic situations. Evidence supporting each statement was graded according to the European Society of Clinical Microbiology and Infection Diseases (ESCMID) grading system. RESULTS: Empirical coverage of A. baumannii is recommended in severe infections (severe sepsis or septic shock) occurring during an A. baumannii outbreak, in an endemic setting, or in a previously colonized patient. For these cases, a polymyxin is suggested as part of the empirical treatment in cases of a high suspicion of a carbapenem-resistant (CR) A. baumannii strain. An institutional program including staff education, promotion of hand hygiene, strict contact and isolation precautions, environmental cleaning, targeted active surveillance, and antimicrobial stewardship should be instituted and maintained to combat outbreaks and endemic situations. CONCLUSIONS: Specific recommendations about prevention and management of A. baumannii infections in the ICU were elaborated by this multidisciplinary panel. The paucity of randomized controlled trials is noteworthy, so these recommendations are mainly based on observational studies and pharmacodynamics modeling.
INTRODUCTION:Acinetobacter baumannii constitutes a dreadful problem in many ICUs worldwide. The very limited therapeutic options available for these organisms are a matter of great concern. No specific guidelines exist addressing the prevention and management of A. baumannii infections in the critical care setting. METHODS: Clinical microbiologists, infectious disease specialists and intensive care physicians were invited by the Chair of the Infection Section of the ESICM to participate in a multidisciplinary expert panel. After the selection of clinically relevant questions, this document provides recommendations about the use of microbiological techniques for identification of A. baumannii in clinical laboratories, antibiotic therapy for severe infections and recommendations to control this pathogen in outbreaks and endemic situations. Evidence supporting each statement was graded according to the European Society of Clinical Microbiology and Infection Diseases (ESCMID) grading system. RESULTS: Empirical coverage of A. baumannii is recommended in severe infections (severe sepsis or septic shock) occurring during an A. baumannii outbreak, in an endemic setting, or in a previously colonized patient. For these cases, a polymyxin is suggested as part of the empirical treatment in cases of a high suspicion of a carbapenem-resistant (CR) A. baumannii strain. An institutional program including staff education, promotion of hand hygiene, strict contact and isolation precautions, environmental cleaning, targeted active surveillance, and antimicrobial stewardship should be instituted and maintained to combat outbreaks and endemic situations. CONCLUSIONS: Specific recommendations about prevention and management of A. baumannii infections in the ICU were elaborated by this multidisciplinary panel. The paucity of randomized controlled trials is noteworthy, so these recommendations are mainly based on observational studies and pharmacodynamics modeling.
Authors: I P Korbila; A Michalopoulos; P I Rafailidis; D Nikita; G Samonis; M E Falagas Journal: Clin Microbiol Infect Date: 2009-09-02 Impact factor: 8.067
Authors: Farrin A Manian; Sandra Griesenauer; Diane Senkel; Janice M Setzer; Sara A Doll; Annie M Perry; Michelle Wiechens Journal: Infect Control Hosp Epidemiol Date: 2011-07 Impact factor: 3.254
Authors: L Silvia Munoz-Price; Philip Carling; Timothy Cleary; Yovanit Fajardo-Aquino; Dennise DePascale; Adriana Jimenez; Michael Hughes; Nicholas Namias; Louis Pizano; Daniel H Kett; Kristopher Arheart Journal: Am J Infect Control Date: 2014-05 Impact factor: 2.918
Authors: Roberto Imberti; Maria Cusato; Paola Villani; Livio Carnevale; Giorgio A Iotti; Martin Langer; Mario Regazzi Journal: Chest Date: 2010-06-17 Impact factor: 9.410
Authors: J Masse; A Elkalioubie; C Blazejewski; G Ledoux; F Wallet; J Poissy; S Preau; S Nseir Journal: Eur J Clin Microbiol Infect Dis Date: 2016-12-20 Impact factor: 3.267
Authors: David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler Journal: Curr Infect Dis Rep Date: 2019-11-16 Impact factor: 3.725
Authors: Anthony D Harris; J Kristie Johnson; Lisa Pineles; Lyndsay M O'Hara; Robert A Bonomo; Kerri A Thom Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191
Authors: Vincent Trebosc; Sarah Gartenmann; Kevin Royet; Pablo Manfredi; Marcus Tötzl; Birgit Schellhorn; Michel Pieren; Marcel Tigges; Sergio Lociuro; Peter C Sennhenn; Marc Gitzinger; Dirk Bumann; Christian Kemmer Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191